Bristol-Myers Squibb Has A Cancer Breakthrough. Here's Why It Should Cut The Price
Matthew Herper (Forbes) $BMY
All For One and One For All? NOPE! Court Rejects FDA’s “One-to-Many” Complex Mixture NCE Exclusivity Decision on VASCEPA; Remands to FDA For Further Proceedings
Kurt Karst (FDA Law Blog) $AMRN
Brodalumab for Psoriasis – what a mess
Paul Rennert (SugarCone Biotech) $AZN $AMGN
The Biotech Hedge Fund Pre-Summer Internship Aptitude Test
David Sable (Forbes)
FDA Researchers Make Case for More Transparency When Drugs are Rejected
Alec Gaffney (Regulatory Focus / RAPS)
‘Exceptional responders’ to cancer drugs draw scrutiny from scientists
Brady Dennis (Washington Post)
Bear argument for $FMI - plenty of stories like this written without the need for FoundationOne?
Matthew Herper (Forbes) $BMY
All For One and One For All? NOPE! Court Rejects FDA’s “One-to-Many” Complex Mixture NCE Exclusivity Decision on VASCEPA; Remands to FDA For Further Proceedings
Kurt Karst (FDA Law Blog) $AMRN
Brodalumab for Psoriasis – what a mess
Paul Rennert (SugarCone Biotech) $AZN $AMGN
The Biotech Hedge Fund Pre-Summer Internship Aptitude Test
David Sable (Forbes)
FDA Researchers Make Case for More Transparency When Drugs are Rejected
Alec Gaffney (Regulatory Focus / RAPS)
‘Exceptional responders’ to cancer drugs draw scrutiny from scientists
Brady Dennis (Washington Post)
Bear argument for $FMI - plenty of stories like this written without the need for FoundationOne?
RSS Feed
